Eli Lilly and Company or MannKind Corporation: Who Manages SG&A Costs Better?

Eli Lilly vs. MannKind: SG&A Cost Management Showdown

__timestampEli Lilly and CompanyMannKind Corporation
Wednesday, January 1, 2014662080000079383000
Thursday, January 1, 20156533000000108402000
Friday, January 1, 2016645200000046928000
Sunday, January 1, 2017658810000074959000
Monday, January 1, 2018597510000079716000
Tuesday, January 1, 2019621380000074669000
Wednesday, January 1, 2020612120000059040000
Friday, January 1, 2021643160000077417000
Saturday, January 1, 2022644040000091473000
Sunday, January 1, 2023694120000094314000
Monday, January 1, 20248593800000
Loading chart...

Cracking the code

Who Manages SG&A Costs Better: Eli Lilly or MannKind?

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Eli Lilly and MannKind Corporation have shown contrasting approaches to handling these costs. From 2014 to 2023, Eli Lilly's SG&A expenses have consistently been higher, averaging around $6.4 billion annually. In contrast, MannKind's expenses have been significantly lower, averaging approximately $78 million per year.

Despite the stark difference in absolute numbers, the trend in SG&A expenses reveals interesting insights. Eli Lilly's expenses have grown by about 5% over the decade, while MannKind's have fluctuated, peaking in 2015 and 2023. This suggests that while Eli Lilly maintains a steady increase, MannKind's cost management is more volatile. Understanding these trends can provide valuable insights into each company's strategic priorities and operational efficiencies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025